Marina Biotech, Inc. (OTCMKTS:MRNA) Files An 8-K Entry into a Material Definitive AgreementItem 1.01. Entry into a Material Definitive Agreement.
On May 17, 2018, Marina Biotech, Inc. (the “Company”) conducted the second and final closing (the “Final Closing”) of the Company’s private placement (the “Private Placement”) of shares of the Series E convertible preferred stock, par value $0.01 per share, of the Company (the “Preferred Stock”), and warrants to purchase shares of the common stock, par value 0.006 per share, of the Company (the “Common Stock”). The initial closing (the “Initial Closing”) of the Private Placement was previously reported by the Company on its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 19, 2018 (the “Prior 8-K”).
In connection with the Final Closing, the Company entered into Subscription Agreements (the “Purchase Agreements”) with certain accredited investors to which the Company sold 478 shares of Preferred Stock at a purchase price of $5,000 per share. Each share of Preferred Stock is initially convertible into shares of Common Stock at a conversion price of $0.50 per share of Common Stock. In addition, each investor received a 5-year warrant (the “Warrants”, and collectively with the Preferred Stock, the “Securities”) to purchase 0.75 shares of Common Stock for each share of Common Stock issuable upon the conversion of the Preferred Stock purchased by such investor at an exercise price equal to $0.55 per share of Common Stock, subject to adjustment thereunder.
The Company received total gross proceeds of approximately $2.39 million from the Final Closing, prior to deducting placement agent fees and estimated expenses payable by the Company associated with the Final Closing. The Company currently intends to use the proceeds of the Private Placement for funding operations, working capital needs, capital expenditures, the repayment of certain liabilities and other general corporate purposes in pursuit of advancing its commercial, clinical and preclinical efforts, including advancing its commercial operations relating to the sale and promotion of the Company’s Prestalia® product. Prestalia is a single-pill fixed dose combination of perindopril arginine, an angiotensin-converting-enzyme inhibitor, and amlodipine besylate, a calcium channel blocker, which has been approved by the U.S. Food and Drug Administration and is marketed in the U.S. The Company received aggregate gross proceeds of approximately $14.1 million from the Initial Closing and the Final Closing, prior to deducting placement agent fees and estimated expenses payable by the Company associated with the Initial Closing and the Final Closing, respectively.
The rights, preferences and privileges of the Preferred Stock issued at the Final Closing are set forth in a Certificate of Designation of Preferences, Rights and Limitations of the Series E Convertible Preferred Stock of Marina Biotech, Inc. (the “Certificate of Designation”) that was filed with the Secretary of State of the State of Delaware on April 16, 2018. The Certificate of Designation was filed as Exhibit 3.1 to the Prior 8-K, and the rights, preferences and privileges of the Preferred Stock were summarized in the Prior 8-K. The form of Warrant that was issued at the Final Closing was filed as Exhibit 4.1 to the Prior 8-K, and the terms and provisions thereof were summarized in the Prior 8-K.
The Securities were offered and sold in a private placement to exemptions from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder. To the extent that any shares of Common Stock are issued in connection with the conversion of the Preferred Stock or the exercise of the Warrants, the Common Stock may not be offered, transferred or sold in the United States absent registration or the availability of an applicable exemption from the registration requirements of the Securities Act.
Maxim Merchant Capital, a division of Maxim Group LLC, acted as placement agent in connection with the Private Placement to a Placement Agency Agreement, dated February 8, 2018 (the “Placement Agency Agreement”). Under the Placement Agency Agreement, the Company agreed: (i) to pay the placement agent a cash commission equal to ten percent (10%) of the aggregate gross proceeds of the Securities sold at each closing (including the conversion into Securities of certain outstanding promissory notes); (ii) to grant to the placement agent or its designees 5-year warrants to purchase shares of Common Stock equal to ten percent (10%) of the aggregate number of shares of Common Stock issuable upon conversion of the Preferred Stock sold at each closing (including the conversion into Securities of certain outstanding promissory notes), at a price equal to the exercise price of the Warrants; (iii) to reimburse the placement agent for certain reasonable and documented expenses; and (iv) to grant the placement agent a right of first refusal to act as lead managing underwriter and book runner for any future public and private equity and public debt offering for a period of fifteen months from the final closing of the Private Placement.
In connection with the Initial Closing and the Final Closing, the Company’s placement agent, to the Placement Agency Agreement, received a cash fee of approximately $1.48 million, plus warrants to purchase 2,958,460 shares of Common Stock at an exercise price equal to $0.55.
The foregoing summaries of the material terms and provisions of the Placement Agency Agreement, the Certificate of Designation, the form of Warrant and the form of Subscription Agreement are not complete and are qualified in their entirety by reference to the full text thereof, copies of each of which are filed herewith as Exhibits 10.1, 3.1, 4.1 and 10.2, respectively, and incorporated by reference herein.
Item 3.02. Unregistered Sales of Equity Securities.
The information set forth in Item 1.01 is incorporated by reference herein in its entirety.
Additional Information
This announcement is neither an offer to sell, nor a solicitation of an offer to buy, any securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. The securities described herein have not been and will not be registered under the Securities Act, or any state securities laws, and unless so registered, may not be offered or sold in the United States except to an exemption from the registration requirements of the Securities Act, and applicable state securities laws.
Item 9.01. Financial Statements and Exhibits.
Marina Biotech, Inc. ExhibitEX-10.1 2 ex10-1.htm February 8,…To view the full exhibit click here
About Marina Biotech, Inc. (OTCMKTS:MRNA)
Marina Biotech, Inc. is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. The Company’s pipeline includes CEQ508, a product in clinical development for the treatment of Familial Adenomatous Polyposis (FAP), and preclinical programs for the treatment of type 1 myotonic dystrophy (DM1) and Duchenne muscular dystrophy (DMD). It creates a range of therapeutics targeting coding and non-coding ribonucleic acid (RNA) through several mechanisms of action, such as RNA interference (RNAi), messenger RNA translational inhibition, exon skipping, microRNA (miRNA) replacement, miRNA inhibition and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action. It has two liposomal-based delivery platforms: SMARTICLES, and the platform, which utilizes amino-based liposomal delivery technology and incorporates a molecule, Di-Alkylated Amino Acid (DiLA2).
